A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30+ lymphomas-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30+ lymphomas

Published:2018-01-26 Issue:3 Volume:12 Page:339-355
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Wang Rong¹,Li Liang¹,Zhang Shenghua¹,Li Yi¹,Wang Xiaofei¹,Miao Qingfang¹,Zhen Yongsu¹

Affiliation:

1. Institute of Medicinal Biotechnology; Chinese Academy of Medical Sciences; Peking Union Medical College; Beijing China

Funder

Chinese Academy of Meteorological Sciences

“Significant New Drug Development” Major Science and Technology Development Projects of China

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Reference45 articles.

1. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience;Angelopoulou;Hematol Oncol,2017

2. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas;Boi;Br J Haematol,2015

3. Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response;Cazzalini;Mutat Res,2010

4. Mitochondrial ribosomal protein S36 delays cell cycle progression in association with p53 modification and p21(WAF1/CIP1) expression;Chen;J Cell Biochem,2007

5. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma;Chen;Blood,2016

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement;Drug Resistance Updates;2024-07

2. A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers;npj Precision Oncology;2024-04-23

3. Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2;International Journal of Biological Macromolecules;2023-12

4. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment;Anti-Cancer Agents in Medicinal Chemistry;2023-04

5. Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation;International Journal of Biological Macromolecules;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3